Analyst firms · Bernstein · NVO

Bernstein NVO price target and rating history

Novo Nordisk A/S (NVO) · Health Care

Bernstein rates Novo Nordisk A/S (NVO) Underperform with a $175 price target, as of its latest action on Mar 18, 2026. It has published 4 rating actions on NVO since January 2025, including 2 upgrades and 0 downgrades. Across 4 firms with a NVO price target in the last 12 months, the median target is $41.50. Bernstein's $175 is 322% above that.

Current rating

Underperform

Price target

$175

Median target, all firms

$41.50

Actions on NVO

4

Every Bernstein rating on NVO

• Mar 18, 2026
  InitiateBernstein starts coverage at Underperform
• Mar 18, 2026
  InitiateBernstein starts coverage at Outperform, price target $175
• Sep 9, 2025
  UpgradeBernstein upgrades to Outperform from Mkt Perform
• Jan 6, 2025
  UpgradeBernstein upgrades to Mkt Perform from Underperform

How other firms rate NVO

Each firm's latest rating and stated target in the last 12 months.

Questions about Bernstein and NVO

What is Bernstein's price target for NVO?

Bernstein's latest stated price target for Novo Nordisk A/S (NVO) is $175, from its action on Mar 18, 2026.

What is Bernstein's rating on NVO?

Bernstein rates NVO Underperform, a bearish rating, as of Mar 18, 2026.

When did Bernstein last change its view on NVO?

On Mar 18, 2026, Bernstein starts coverage at Underperform.

How does Bernstein's NVO target compare with other analysts?

Across 4 firms with a NVO price target in the last 12 months, the median target is $41.50. Bernstein's $175 is 322% above that.

More NVO rating histories

• Morgan Stanley7
• Deutsche Bank4
• HSBC3
• UBS3

All Bernstein ratingsNVO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.